Member Info for moonparty

Hi Stakis,

I use II for SIPP, ISA and trading - £22 a month for all 3, then £3.99 a trade, but you get some free trades every month (sorry can't remember how many).

Definitely competitive if you have an ISA and/or SIPP, but probably not for trading only.

There's a range of free apps like Degiro, Trading212 (which I use for very small scale index trading), that offer no-fee stock purchases, but not good for AIM as they don't get the best price - I think their ‘fee’ is to shaft you on the spread.

Not aware of any providers that provide good services and cover AIM and other illiquid shares that are devoid of fees.

For me, II have always done well and handled dividends, open offers, corporate actions etc.. without fault (so far).

Violin,

"Just wish he would show more confidence by buying a few shares on the open market."

I'm not sure he, or any of the senior/operational staff, can?

They may have access to the ongoing scan results? Hope someone more aware of the protocols can answer this better.

Phil would certainly know about any deal already struck for phase 3 which would put him in a closed period (even if dependent on next clinical results).

Vulpes are one step removed from day-to-day operations so don't have that access which is why they were able to purchase.

"Data from the first three cohorts has shown compelling efficacy in combination with checkpoint inhibitors"

We haven't had official results from cohort 3 yet (iscib1+), so this is good news!

"we’re approaching some critical inflection points that will provide a solid

foundation for potential licensing partnerships"

Especially liked this 😀

You can currently sell 250K at 9.8p, 400K at 9.5p on auto, so still plenty of demand for shares.

Thanks Rob, useful info.

Rob, I am intrigued, how did you know?

Rob, either you are incredibly insightful or you have a real-time subscription 😀

As discussed yesterday, unusual trades. Will we get a holdings RNS soon?

You can sell up to 500,000 right now on auto, for 9.255p. (9.727p for 100K)

Somebody clearly wants shares.

Agreed darientaylor,

They key test will be if NAV pre share is rising - we will have to wait till half year report in September. Watch this fly if NAV has increased!

No ideas if it will increase or not - but the clues look good, and every share buy-back increases NAV per share, so odds stacked in our favour.

BMS doing a deal with others in no way precludes a deal with Scancell.

They are a big company - why on earth wouldn't they invest in both, they know better than us the failure rates so they need more than one option!

Phil obviously going to lead or add gravitas to discussions. Very good sign that things are getting serious now. IMO.

"As Head of Program Management, you will play a critical role in aligning cross-functional teams, optimising program delivery, and driving our mission forward in developing cutting-edge immunotherapies."

Https://www.linkedin.com/posts/scancell-limited_hiring-activity-7331756208934043648-dKUa?utm_source=share&utm_medium=member_android&rcm=ACoAAAO3ZOMBBBUycVJ1yPRWhTZCRwZFYO5dBQ0

No mention of SCIB1, this is a strong hint that iSCIB1+ is performing as well or better.

Very sad news, was always a genuine contributor and a very pleasant fellow.

Can't blame him, he's not very good at reflecting 😀

Perfect storm for Scancell SP - cancer vaccines out of favour, AIM out of favour, biotech out of favour, risk out of favour. Nothing whatsoever to do with the tech or trials.

Seems to be turning around now - vaccines back in vogue (and interestingly DNA vaccines getting talked about along with RNA), biotech getting a bit more attention this year in terms of M&A. Not sure about risk and AIM - we still have challenges there, just need to de-risk further with good trial resutls and move to Nasdaq!

I think this is highly likely modi1 will be added to the partnership, if scope shows success.

Https://www.linkedin.com/posts/scancell-limited_hiring-activity-7323271359613054976-Wld7?utm_source=share&utm_medium=member_android&rcm=ACoAAAO3ZOMBBBUycVJ1yPRWhTZCRwZFYO5dBQ0

Fair point burble, I was thinking it won't delay the decision on which vaccine to take forward and thus the start of the official registration trial admin. But you are right that cohort 4 may have an impact, as changing delivery method would require the supporting data. Not sure if it is possible to push ahead and confirm delivery method later on in the process?